NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
June 26, 2024 16:39 ET
|
NeOnc Technologies Holdings, Inc.
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
April 24, 2023 11:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
March 06, 2023 08:00 ET
|
NeOnc Technologies Holdings, Inc.
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
National Brain Tumor Society & St. Baldrick's Foundation Partner to Defeat Deadliest Pediatric Cancer
October 06, 2016 14:53 ET
|
National Brain Tumor Society
BOSTON, MA--(Marketwired - October 06, 2016) - National Brain Tumor Society (NBTS), the largest nonprofit organization in the United States dedicated to the global brain tumor community, announced...